Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

8.2K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
8.2K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

802
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
802

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence for Astrophysical Muon Neutrinos from the Northern Sky with IceCube.

Physical review letters·2015
Same author

Development of a general analysis and unfolding scheme and its application to measure the energy spectrum of atmospheric neutrinos with IceCube: IceCube Collaboration.

The European physical journal. C, Particles and fields·2015
Same author

Flavor Ratio of Astrophysical Neutrinos above 35 TeV in IceCube.

Physical review letters·2015
Same author

[Positron emission tomography 2013 in Germany. Results of the query and current status].

Nuklearmedizin. Nuclear medicine·2015
Same author

Observation of high-energy astrophysical neutrinos in three years of IceCube data.

Physical review letters·2014
Same author

Nuclear medicine training and practice in Germany.

European journal of nuclear medicine and molecular imaging·2013
Same journal

[Transition in Differences of Sex Development (DSD): From Human Being to Person].

Aktuelle Urologie·2026
Same journal

[Posterior Urethral Valves: A Pediatric Urological Condition with Lifelong Relevance].

Aktuelle Urologie·2026
Same journal

[Current Developments and Strategies for Infection Prevention and Management in Penile Implant Surgery].

Aktuelle Urologie·2026
Same journal

[Transition of Patients with Neurogenic Bladder Dysfunction: Challenges and Unmet Needs in Adult Care].

Aktuelle Urologie·2026
Same journal

[Hypospadias: A Long-Term Problem?]

Aktuelle Urologie·2026
Same journal

[Urogenital Symptoms in Cyclists and Reduction of Perineal Pressure Load Using a Prostate Volume-Adapted Bicycle Saddle].

Aktuelle Urologie·2026
See all related articles

Related Experiment Video

Updated: Apr 19, 2026

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

19.3K

[Ga-68-PSMA PET/CT for prostate cancer].

D Hellwig1, J Moosbauer2, C Eilles2

  • 1Klinik für Nuklearmedizin, Universitätsklinikum des Saarlandes, Homburg.

Aktuelle Urologie
|December 19, 2014
PubMed
Summary
This summary is machine-generated.

New Gallium-68 (Ga-68) radiopharmaceuticals targeting prostate-specific membrane antigen (PSMA) offer improved imaging for prostate cancer detection. These PSMA PET/CT agents show higher contrast and diagnostic accuracy than older methods.

More Related Videos

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

1.1K
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

2.1K

Related Experiment Videos

Last Updated: Apr 19, 2026

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

19.3K
Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

1.1K
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

2.1K

Area of Science:

  • Nuclear medicine
  • Oncology
  • Radiopharmaceutical development

Background:

  • Prostate-specific membrane antigen (PSMA) is overexpressed in all stages of prostate cancer, including castration-resistant forms.
  • PSMA's enzymatic activity allows for the development of specific small molecule inhibitors.
  • Existing diagnostic tools like choline-PET/CT have limitations in prostate cancer imaging.

Purpose of the Study:

  • To introduce a novel Ga-68 radiopharmaceutical for PSMA-PET/CT imaging in prostate cancer.
  • To evaluate the diagnostic performance of this new agent compared to choline-PET/CT.
  • To explore the potential of PSMA-targeted agents in prostate cancer theranostics.

Main Methods:

  • Development of a new radiopharmaceutical by coupling a glutamate-urea-lysine binding motif with the HBED-CC chelator for Ga-68 complexation.
  • Administration of the Ga-68-PSMA radiopharmaceutical for PET/CT imaging in patients with prostate carcinoma.
  • Comparison of image quality, signal contrast, and diagnostic accuracy with choline-PET/CT.

Main Results:

  • The novel Ga-68-PSMA radiopharmaceutical demonstrated superior image quality compared to choline-PET/CT.
  • Higher contrast in the PET signal was observed with the new PSMA-targeted agent.
  • Improved diagnostic accuracy was reported in the initial patient study.

Conclusions:

  • Ga-68-PSMA-PET/CT represents a significant advancement in prostate cancer diagnostics.
  • This new imaging modality offers enhanced visualization and accuracy for prostate cancer detection.
  • Further development of PSMA radiopharmaceuticals holds promise for improved prostate cancer management and theranostics.